[go: up one dir, main page]

MX2020004830A - Medios y metodo para preparar vectores virales y usos de los mismos. - Google Patents

Medios y metodo para preparar vectores virales y usos de los mismos.

Info

Publication number
MX2020004830A
MX2020004830A MX2020004830A MX2020004830A MX2020004830A MX 2020004830 A MX2020004830 A MX 2020004830A MX 2020004830 A MX2020004830 A MX 2020004830A MX 2020004830 A MX2020004830 A MX 2020004830A MX 2020004830 A MX2020004830 A MX 2020004830A
Authority
MX
Mexico
Prior art keywords
same
viral vectors
preparing viral
preparing
compositions
Prior art date
Application number
MX2020004830A
Other languages
English (en)
Inventor
Robert Emil Hodge
Brian K Kaspar
James Michael Hatfield
Joseph Balleydier
Allan Arman Kaspar
Original Assignee
Avexis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Avexis Inc filed Critical Avexis Inc
Publication of MX2020004830A publication Critical patent/MX2020004830A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0091—Purification or manufacturing processes for gene therapy compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/64—General methods for preparing the vector, for introducing it into the cell or for selecting the vector-containing host
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y115/00—Oxidoreductases acting on superoxide as acceptor (1.15)
    • C12Y115/01—Oxidoreductases acting on superoxide as acceptor (1.15) with NAD or NADP as acceptor (1.15.1)
    • C12Y115/01001—Superoxide dismutase (1.15.1.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14151—Methods of production or purification of viral material

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Mycology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)

Abstract

Se proporcionan métodos para preparar y purificar partículas virales, y composiciones y usos que comprenden las mismas.
MX2020004830A 2017-11-08 2018-11-01 Medios y metodo para preparar vectores virales y usos de los mismos. MX2020004830A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762583035P 2017-11-08 2017-11-08
PCT/US2018/058744 WO2019094253A1 (en) 2017-11-08 2018-11-01 Means and method for preparing viral vectors and uses of same

Publications (1)

Publication Number Publication Date
MX2020004830A true MX2020004830A (es) 2020-11-11

Family

ID=64362706

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020004830A MX2020004830A (es) 2017-11-08 2018-11-01 Medios y metodo para preparar vectores virales y usos de los mismos.

Country Status (15)

Country Link
US (2) US12168777B2 (es)
EP (2) EP4585229A2 (es)
JP (2) JP7587422B2 (es)
KR (1) KR20200086292A (es)
CN (2) CN111566220A (es)
AU (2) AU2018365677B2 (es)
BR (1) BR112019013268A2 (es)
CA (1) CA3082136A1 (es)
CL (1) CL2020001193A1 (es)
CO (1) CO2020006900A2 (es)
IL (2) IL314692A (es)
MX (1) MX2020004830A (es)
SG (1) SG11202004406VA (es)
TW (1) TWI827560B (es)
WO (1) WO2019094253A1 (es)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11219696B2 (en) * 2008-12-19 2022-01-11 Nationwide Children's Hospital Delivery of polynucleotides using recombinant AAV9
MX2020000713A (es) * 2017-07-17 2020-08-31 Spark Therapeutics Inc Metodos de aferesis y sus usos.
BR112019013268A2 (pt) 2017-11-08 2019-12-17 Avexis Inc meios e métodos para a preparação de vetores virais e usos dos mesmos
KR102812672B1 (ko) * 2018-06-08 2025-05-28 노파르티스 아게 약물 산물 효능을 측정하기 위한 세포-기반 분석
JP2021534154A (ja) * 2018-08-15 2021-12-09 バイオジェン・エムエイ・インコーポレイテッドBiogen MA Inc. 脊髄性筋萎縮症のための併用療法
AU2020273182A1 (en) * 2019-04-10 2021-12-02 Prevail Therapeutics, Inc. Gene therapies for lysosomal disorders
US10801042B1 (en) * 2019-07-15 2020-10-13 Vigene Biosciences, Inc. Use of ion concentrations to increase the packaging efficiency of recombinant adeno-associated virus
CN114423869A (zh) 2019-07-19 2022-04-29 旗舰先锋创新Vi有限责任公司 重组酶组合物和使用方法
US20220307053A1 (en) 2019-07-25 2022-09-29 Novartis Ag Regulatable expression systems
EP4010033A4 (en) * 2019-08-08 2023-05-24 Biogen MA Inc. BIOLOGICAL ACTIVITY TEST FOR VIRAL VECTOR PRODUCTION
JP2022554267A (ja) * 2019-10-30 2022-12-28 アミカス セラピューティックス インコーポレイテッド 組換えｃｄｋｌ５タンパク質、遺伝子療法、及び製造方法
US20230038151A1 (en) * 2020-01-28 2023-02-09 Lonza Walkersville, Inc. Methods of determining viral titer
US20230220402A1 (en) 2020-04-17 2023-07-13 Friedrich Miescher Institute For Biomedical Research Use of an orphan motif to increase expression of a heterologous transgene
CN112121179A (zh) * 2020-09-15 2020-12-25 山东兴瑞生物科技有限公司 一种组合物及其在治疗脊髓性肌萎缩症中的应用
CA3198675A1 (en) * 2020-10-15 2022-04-21 Prevail Therapeutics, Inc. Recombinant adeno-associated virus compositions and methods for producing same
CN112251440A (zh) * 2020-10-29 2021-01-22 大连理工大学 一种CRISPR/Cas9基因载体、其制备方法及应用
CN116529381A (zh) 2020-12-03 2023-08-01 弗里德里克·米谢尔生物医学研究所 利用孤儿基序和CpG密度的组合来控制异源转基因的表达
WO2022220273A1 (ja) * 2021-04-15 2022-10-20 国立大学法人東京大学 ウイルス粒子の製造方法
US20240252684A1 (en) 2021-07-30 2024-08-01 Tune Therapeutics, Inc. Compositions and methods for modulating expression of methyl-cpg binding protein 2 (mecp2)
US20240254483A1 (en) 2021-07-30 2024-08-01 Tune Therapeutics, Inc. Compositions and methods for modulating expression of frataxin (fxn)
WO2023012514A1 (en) * 2021-08-04 2023-02-09 Takeda Pharmaceutical Company, Limited Adeno-associated virus separation on a cation exchanger
US20240398985A1 (en) 2021-09-16 2024-12-05 Novartis Ag Novel transcription factors
WO2023061499A1 (en) * 2021-10-15 2023-04-20 Shanghai Vitalgen Biopharma Co., Ltd. Recombinant adeno-associated viral vectors for treating spinal muscular atrophy
JP2024539123A (ja) 2021-10-25 2024-10-28 ノバルティス アーゲー アデノ随伴ウイルス（ａａｖ）送達を改善する方法
EP4436982A1 (en) 2021-11-24 2024-10-02 Novartis AG Modulators of adeno-associated virus transduction and uses thereof
JP2025517628A (ja) 2022-05-06 2025-06-10 ノバルティス アーゲー 新規の組換えａａｖ ｖｐ２融合ポリペプチド
WO2024015881A2 (en) 2022-07-12 2024-01-18 Tune Therapeutics, Inc. Compositions, systems, and methods for targeted transcriptional activation
CN114990162A (zh) * 2022-07-18 2022-09-02 苏州吉纳星辰生物技术有限公司 一种降低aav病毒载体生产中质粒残留的方法
WO2024027632A1 (en) * 2022-08-01 2024-02-08 Skyline Therapeutics (Shanghai) Co., Ltd. Novel plasmid backbone to reduce dna impurities in raav preparation
CN115554418B (zh) * 2022-11-22 2023-04-14 四川至善唯新生物科技有限公司 一种重组腺相关病毒载体的药物组合物及其用途
WO2024163683A2 (en) 2023-02-01 2024-08-08 Tune Therapeutics, Inc. Systems, compositions, and methods for modulating expression of methyl-cpg binding protein 2 (mecp2) and x-inactive specific transcript (xist)
WO2024163678A2 (en) 2023-02-01 2024-08-08 Tune Therapeutics, Inc. Fusion proteins and systems for targeted activation of frataxin (fxn) and related methods
WO2024194280A1 (en) 2023-03-21 2024-09-26 F. Hoffmann-La Roche Ag Method for the production of recombinant aav particle preparations
WO2024252182A1 (en) * 2023-06-08 2024-12-12 Meiragtx Uk Ii Limited Cation exchange chromatography for aav capture

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5173418A (en) 1985-05-10 1992-12-22 Benzon Pharma, A/S Production in Escherichia coli of extracellular Serratia spp. hydrolases
US5139941A (en) 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
US5173414A (en) 1990-10-30 1992-12-22 Applied Immune Sciences, Inc. Production of recombinant adeno-associated virus vectors
EP0728214B1 (en) 1993-11-09 2004-07-28 Medical College Of Ohio Stable cell lines capable of expressing the adeno-associated virus replication gene
CA2176117C (en) 1993-11-09 2006-01-03 Terence R. Flotte Generation of high titers of recombinant aav vectors
US5658785A (en) 1994-06-06 1997-08-19 Children's Hospital, Inc. Adeno-associated virus materials and methods
US5856152A (en) 1994-10-28 1999-01-05 The Trustees Of The University Of Pennsylvania Hybrid adenovirus-AAV vector and methods of use therefor
EP0796339A1 (en) 1994-12-06 1997-09-24 Targeted Genetics Corporation Packaging cell lines for generation of high titers of recombinant aav vectors
US6001650A (en) 1995-08-03 1999-12-14 Avigen, Inc. High-efficiency wild-type-free AAV helper functions
FR2737730B1 (fr) 1995-08-10 1997-09-05 Pasteur Merieux Serums Vacc Procede de purification de virus par chromatographie
AU722196B2 (en) 1995-08-30 2000-07-27 Genzyme Corporation Chromatographic purification of adenovirus and AAV
ES2317646T3 (es) 1995-09-08 2009-04-16 Genzyme Corporation Vectores aav mejorados para terapia genica.
US5910434A (en) 1995-12-15 1999-06-08 Systemix, Inc. Method for obtaining retroviral packaging cell lines producing high transducing efficiency retroviral supernatant
CN1233291A (zh) 1996-09-06 1999-10-27 宾西法尼亚大学托管会 重组腺伴随病毒定向基因治疗的方法
US6756207B1 (en) 1997-02-27 2004-06-29 Cellomics, Inc. System for cell-based screening
EP1009808B1 (en) 1997-09-05 2012-12-05 Genzyme Corporation Methods for generating high titer helper-free preparations of recombinant aav vectors
US6258595B1 (en) 1999-03-18 2001-07-10 The Trustees Of The University Of Pennsylvania Compositions and methods for helper-free production of recombinant adeno-associated viruses
CA2406743A1 (en) 2000-04-28 2001-11-08 The Trustees Of The University Of Pennsylvania Recombinant aav vectors with aav5 capsids and aav5 vectors pseudotyped in heterologous capsids
DK2573170T3 (en) 2001-12-17 2018-04-09 Univ Pennsylvania Sequences of adeno-associated virus (AAV) serotype 9, vectors containing them, and their use
WO2004113494A2 (en) 2003-05-21 2004-12-29 Avigen, Inc. Methods for producing preparations of recombinant aav virions substantially free of empty capsids
US9233131B2 (en) 2003-06-30 2016-01-12 The Regents Of The University Of California Mutant adeno-associated virus virions and methods of use thereof
US9441244B2 (en) 2003-06-30 2016-09-13 The Regents Of The University Of California Mutant adeno-associated virus virions and methods of use thereof
JP2007522796A (ja) 2003-11-07 2007-08-16 ユニヴァーシティ オブ フロリダ リサーチ ファウンデーション，インク． 神経前駆細胞の培養と分化
DK3290513T3 (da) * 2004-06-01 2022-12-12 Genzyme Corp Sammensætninger og fremgangsmåder til forhindring af aav-vektoraggregering
HUE027486T2 (en) 2005-06-23 2016-09-28 Isis Pharmaceuticals Inc Preparations and methods for modifying SMN2-Splicing
EP2058401A1 (en) * 2007-10-05 2009-05-13 Genethon Widespread gene delivery to motor neurons using peripheral injection of AAV vectors
MX2011000125A (es) 2008-06-30 2011-02-25 Centocor Ortho Biotech Inc Diferenciacion de celulas madre pluripotentes.
WO2010071832A1 (en) 2008-12-19 2010-06-24 Nationwide Children's Hospital Delivery of polynucleotides across the blood brain barrier using recombinant aav9
US9415121B2 (en) 2008-12-19 2016-08-16 Nationwide Children's Hospital Delivery of MECP2 polynucleotide using recombinant AAV9
US11219696B2 (en) 2008-12-19 2022-01-11 Nationwide Children's Hospital Delivery of polynucleotides using recombinant AAV9
HRP20181423T1 (hr) 2009-05-02 2018-11-30 Genzyme Corporation Genska terapija za neurodegenerativne poremećaje
US8980853B2 (en) 2009-06-17 2015-03-17 Isis Pharmaceuticals, Inc. Compositions and methods for modulation of SMN2 splicing in a subject
SG181685A1 (en) 2009-12-23 2012-07-30 Centocor Ortho Biotech Inc Differentiation of human embryonic stem cells
IN2012DN06629A (es) * 2010-01-28 2015-10-23 Philadelphia Children Hospital
DE102012007232B4 (de) 2012-04-07 2014-03-13 Susanne Weller Verfahren zur Herstellung von rotierenden elektrischen Maschinen
JP2015519085A (ja) 2012-06-14 2015-07-09 ヤンセン バイオテツク，インコーポレーテツド 多能性細胞の処理
AU2013279284A1 (en) 2012-06-21 2015-01-29 Association Institut De Myologie Widespread gene delivery of gene therapy vectors
US20150252384A1 (en) 2012-08-01 2015-09-10 National Children's Hospital Intrathecal delivery of recombinant adeno-associated virus 9
KR20200060536A (ko) 2013-05-01 2020-05-29 젠자임 코포레이션 척수성 근위축증을 치료하기 위한 조성물 및 방법
US10072250B2 (en) 2013-07-11 2018-09-11 Takara Bio Inc. Method for manufacturing non-enveloped virus
AU2014293460B2 (en) 2013-07-26 2019-10-24 University Of Iowa Research Foundation Methods and compositions for treating brain diseases
US20160272976A1 (en) 2013-08-27 2016-09-22 Research Institute Ata Nationwide Children's Hospital Products and methods for treatment of familial amyotrophic lateral sclerosis
JP2015092462A (ja) 2013-09-30 2015-05-14 Tdk株式会社 正極及びそれを用いたリチウムイオン二次電池
JP6202701B2 (ja) 2014-03-21 2017-09-27 株式会社日立国際電気 基板処理装置、半導体装置の製造方法及びプログラム
EP2933335A1 (en) 2014-04-18 2015-10-21 Genethon A method of treating peripheral neuropathies and motor neuron diseases
WO2016004319A1 (en) * 2014-07-02 2016-01-07 University Of Florida Research Foundation, Inc. Compositions and methods for purifying recombinant adeno-associated virus
JP6197169B2 (ja) 2014-09-29 2017-09-20 東芝メモリ株式会社 半導体装置の製造方法
JP6754361B2 (ja) 2014-12-16 2020-09-09 ボード オブ リージェンツ オブ ザ ユニバーシティ オブ ネブラスカ 若年型バッテン病のための遺伝子療法
EP3054007A1 (en) 2015-02-09 2016-08-10 Institut National De La Sante Et De La Recherche Medicale (Inserm) Recombinant adeno-associated virus particle purification comprising an immuno-affinity purification step
EP3054006A1 (en) 2015-02-09 2016-08-10 Institut National De La Sante Et De La Recherche Medicale (Inserm) Recombinant adeno-associated virus particle purification with multiple-step anion exchange chromatography
US11098286B2 (en) 2015-12-11 2021-08-24 The Trustees Of The University Of Pennsylvania Scalable purification method for AAV9
LT3436051T (lt) * 2016-03-31 2021-11-25 Spark Therapeutics, Inc. Kolonėlėmis pagrįstas visiškai keičiamo masto raav gavimo būdas
SG11201808176TA (en) 2016-04-15 2018-10-30 The Trustees Of The Univ Of Pennsyvania Gene therapy for treating mucopolysaccharidosis type ii
EP3299456A1 (en) 2016-09-26 2018-03-28 Université de Strasbourg Recombinant dgkk gene for fragile x syndrome gene therapy
KR102641846B1 (ko) 2016-11-17 2024-02-27 네이션와이드 칠드런스 하스피탈 인코포레이티드 메틸-CpG 결합 단백질 2를 암호화하는 재조합 아데노-관련 바이러스의 경막 내 전달
EP3652324A1 (en) 2017-07-08 2020-05-20 Genethon Treatment of spinal muscular atrophy
BR112019013268A2 (pt) 2017-11-08 2019-12-17 Avexis Inc meios e métodos para a preparação de vetores virais e usos dos mesmos
KR102812672B1 (ko) 2018-06-08 2025-05-28 노파르티스 아게 약물 산물 효능을 측정하기 위한 세포-기반 분석

Also Published As

Publication number Publication date
AU2025203480A1 (en) 2025-06-05
JP2025017361A (ja) 2025-02-05
US20250066813A1 (en) 2025-02-27
AU2018365677B2 (en) 2025-04-03
JP2021502123A (ja) 2021-01-28
WO2019094253A1 (en) 2019-05-16
IL314692A (en) 2024-10-01
EP3707264A1 (en) 2020-09-16
CO2020006900A2 (es) 2020-06-19
TW201930590A (zh) 2019-08-01
CN111566220A (zh) 2020-08-21
AU2018365677A1 (en) 2020-05-14
JP7587422B2 (ja) 2024-11-20
CA3082136A1 (en) 2019-05-16
IL274430A (en) 2020-06-30
US12168777B2 (en) 2024-12-17
RU2020118557A (ru) 2021-12-08
IL274430B1 (en) 2024-09-01
SG11202004406VA (en) 2020-06-29
CL2020001193A1 (es) 2020-11-13
EP4585229A2 (en) 2025-07-16
CN119033965A (zh) 2024-11-29
TWI827560B (zh) 2024-01-01
IL274430B2 (en) 2025-01-01
BR112019013268A2 (pt) 2019-12-17
RU2020118557A3 (es) 2022-04-15
KR20200086292A (ko) 2020-07-16
US20210317474A1 (en) 2021-10-14

Similar Documents

Publication Publication Date Title
MX2020004830A (es) Medios y metodo para preparar vectores virales y usos de los mismos.
CO2018011804A2 (es) Receptores quiméricos de flt3 y métodos de uso de los mismos
CR20180013A (es) Anticuerpos anti-tau y métodos de uso.
ECSP18094829A (es) Anticuerpos anti-cd40 y sus usos
CO2018002196A2 (es) Proteínas de fusión de factor ix y métodos para producirlas y utilizarlas
MX2024011869A (es) Anticuerpos anti-tau y metodos de uso
BR112019012343A2 (pt) anticorpos il-11ra
MX2019003735A (es) Formulaciones diluibles de cannabinoides y procesos para su preparacion.
CR20190271A (es) Anticuerpos antitau y métodos de uso
UY37523A (es) Anticuerpos anti-ox40 y sus usos
BR112019012342A2 (pt) anticorpos il-11
MX379487B (es) Inmunomoduladores.
EA201891532A1 (ru) Композиции и способы лечения гемоглобинопатий
BR112017003414A2 (pt) composições compreendendo caseína e métodos para produzir as mesmas
MX2017007049A (es) Anticuerpos anti-cd79b y métodos de uso.
CO2020003120A2 (es) Activador akt3 y específico usos de este
CR20160362A (es) Anticuerpos anti-jagged1 y metodos de uso
CL2019002605A1 (es) Formulaciones que contienen proteínas de unión pd-1 y métodos de fabricación de las mismas.
BR112017013568A2 (pt) compostos bicíclicos fundidos para o tratamento de doenças
BR112017025711A2 (pt) ?composições, processo para preparação de siloxanos modificados por poliéter e uso das composições inovadoras?
MX389001B (es) Moduladores de interacción de sestrina-gator2 y sus usos.
MX2017013875A (es) Ciertos inhibidores de la proteína quinasa.
MX2017002469A (es) Composiciones de matrices extracelulares.
MX386916B (es) Partículas de proteína porosas como portadoras para activos.
MX2019010492A (es) Kits y metodos para preparar composiciones de plaquetas con patogeno inactivado.

Legal Events

Date Code Title Description
GD Licence granted